Blend is discovering and developing integrative nanomedicines. Using an integrative drug development engine combining proprietary compounds, patented nanoengineering, biomarkers and diagnostics, Blend is discovering and developing first in class transformational nanomedicines for patients. Blend’s nanomedicines are based on platform technologies that can be combined in a modular manner to create a series of uniquely targeted nanomedicines deploying the most potent of payloads derived from various classes of medicines. These innovations have unlocked the efficacy of drugs, have the potential to improve the safety of these medicines, and lead to entirely new classes of therapeutics drugs that will revolutionize the treatment of many patients, extending the length and quality of their lives.
Current Team (7)Update
Funding Rounds (3) - $24.8MUpdate
Board Members and Advisors (4)Update
134 Coolidge Avenue
Watertown, MA 02472